Ovarian Carcinoma

Major improvements are needed in the treatment of advanced ovarian cancer. While the introduction of, initially, cisplatin and, later, taxanes has improved the outcome of these patients, less than 25% of stage III patients achieve long-term disease-free survival (DFS) with current multimodal management, including debulking surgery and conventional-dose chemotherapy. For patients with relapsed disease, salvage conventional-dose chemotherapy is not curative. Stage IV patients have a 5-year survival of less than 5%.

0 0

Post a comment